Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001968202-24-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-25 | 2024-01-23+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $949.36 | -1,128 | 23.5K | -5% | -$1.07M |
| DM | 2024-01-25 | 2024-01-23+ | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,600 | 24.1K | +7% | +$606.4K |
| DM | 2024-01-25 | 2024-01-23+ | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,600 | 13.1K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | F | D | 776 | $948.50 | 23,308 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-24 | M | A | 500 | $378.98 | 23,808 | D | — | — | |
| 3 | Common | Common Stock | 2024-01-24 | F | D | 352 | $951.26 | 23,456 | D | — | — | |
| 4 | Common | Common Stock | 2024-01-23 | M | A | 1,100 | $378.98 | 24,084 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-24 | M | D | 500 | $0.00 | 12,587 | D | $378.98 · — to 2027-12-12 | 500 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-23 | M | D | 1,100 | $0.00 | 13,087 | D | $378.98 · — to 2027-12-12 | 1,100 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |